Vanda Pharmaceuticals (VNDA) Free Cash Flow (2010 - 2026)

Vanda Pharmaceuticals has disclosed Free Cash Flow across 17 years of filings, most recently posting -$50.4 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$50.4 million, down 50.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$127.3 million (down 121.8% YoY), and the FY2025 annual result was -$110.4 million, down 579.76% from the prior year.
• Free Cash Flow came in at -$50.4 million for Q1 2026 at Vanda Pharmaceuticals, down from -$29.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $31.8 million in Q1 2023 to a low of -$50.4 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$4.0 million (2023), against an average of -$7.8 million.
• Across the five-year window, Free Cash Flow surged 699.6% in 2023 and plunged 1353.42% in 2025, its largest moves.
• Vanda Pharmaceuticals' Free Cash Flow stood at $9.2 million in 2022, then plunged by 143.54% to -$4.0 million in 2023, then surged by 49.03% to -$2.0 million in 2024, then slumped by 1353.42% to -$29.5 million in 2025, then slumped by 70.87% to -$50.4 million in 2026.
• The last three Free Cash Flow figures came in at -$50.4 million (Q1 2026), -$29.5 million (Q4 2025), and -$31.8 million (Q3 2025), per Business Quant data.